Exact Sciences
EXAS
$66.43
Share price
0.74%
Change (1 day)
39.59%
Change (1 year)
Categories
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer.
Operating Margin for Exact Sciences (EXAS)
Operating Margin as of September 2023 (TTM): -30.34%
According to Exact Sciences's latest financial reports and stock price the company's current Operating Margin is -30.34%. At the end of 2022 the company had an Operating Margin of -30.35%.
Operating Margin history for Exact Sciences from 2013 to 2012
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2022 | -30.35% | -36.34% |
| 2021 | -47.68% | -17.04% |
| 2020 | -57.47% | 87.32% |
| 2019 | -30.68% | -20.35% |
| 2018 | -38.52% | -10.58% |
| 2017 | -43.08% | -74.4% |
| 2016 | -168.26% | -57.95% |
| 2015 | -400.14% | -92.81% |
| 2014 | -5,564.40% | 395.74% |
| 2013 | -1,122.44% | -11.27% |
| 2012 | -1,264.99% | 82.71% |
| 2011 | -692.36% | 212.87% |
| 2010 | -221.29% | 14.31% |
| 2009 | -193.59% | -82.09% |
| 2008 | -1,080.85% | 171.83% |
| 2007 | -397.61% | 39.94% |
| 2006 | -284.13% | -19.54% |
| 2005 | -353.13% | -9.21% |
| 2004 | -388.96% | -60.87% |
| 2003 | -994.07% | -70.16% |
| 2002 | -3,331.44% | -93.52% |
| 2001 | -51,406.44% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 18.21% | -160.02% | 🇫🇷 France |
 Veracyte VCYT | -11.67% | -61.54% | 🇺🇸 USA |
 Antares Pharma ATRS | 31.38% | -203.44% | 🇺🇸 USA |
 Myriad Genetics MYGN | -20.72% | -31.71% | 🇺🇸 USA |
 Biocept
BIOC | -124.57% | 310.58% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.